What do systematic reviews say?

Early vs deferred AST

Early probably leads to lower time to death of any cause (here: all‐cause mortality at 5 years) compared with deferred AST (moderate certainty).

• Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer 2019 · Cochrane Headline outcomes only
  HR 0.82 [0.75, 0.9]
  10 studies · 4767 participants
  Moderate